With the launch of five adalimumab biosimilars into the European market since October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), Hyrimoz (Sandoz), and Idacio (Fresenius Kabi)—competition within the already dynamic autoimmune therapy market will only increase. The first biosimilars to launch in this therapy area (infliximab  and Benepali ) have now been available for several years in Europe, and their uptake has been robust. With more adalimumab biosimilars forecast to launch in Europe over the next years, it will be critical for stakeholders active in the immune space to understand the dynamics of how adalimumab biosimilars will affect the uptake of the reference brand, Humira (AbbVie), and other originator biologics. Along with physician familiarity, awareness and perceptions of biosimilars in general, and the launch of adalimumab biosimilars in particular, we explore the drivers of and barriers to the uptake of adalimumab biosimilars in Germany. We discuss promotional efforts, as well as prescriber and nonprescriber profiles, and benchmark the agents against other available biosimilars to better understand the dynamics of the German biosimilar market.
Emerging Biosimilars is a three-wave series based on primary research data collected at one, six, and twelve months postcommercial launch. The research captures physicians’ awareness, perceptions, and use of biosimilars, as well as their impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Wave 1: February 2019
Wave 2: July 2019
Wave 3: January 2020
Survey of 30 rheumatologists, 30 gastroenterologists, and 30 dermatologists
Key metrics included